Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 298 participants.

Also called NCT02282813

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 298 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02282813
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02282813. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2016-08-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
Condition
Hyperparathyroidism, Secondary
Condition
Vitamin D Deficiency
Intervention (Drug)
CTAP101 Capsules
Intervention (Drug)
Calcitriol
Intervention (Drug)
Doxercalciferol
Intervention (Drug)
Paricalcitol
Lead sponsor
OPKO Health, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02282813
Content hash
25b3d8b26e0d89e061347ec65dc869ef692ed233f3c01cd8f85222720e7adaab